HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2006-0807v1 25/8/2066    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yoon, S. H. Articles by Ha, Y. Search for Related Content PubMed PubMed Citation Articles by Yoon, S. H. Articles by Ha, Y.

TRANSLATIONAL AND CLINICAL RESEARCH

Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage-Colony Stimulating Factor: Phase I/II Clinical Trial

^aInha Neural Repair Center,
^bDepartments of Neurosurgery,
^cPhysiology,
^dAnesthesiology,
^eDiagnostic Pathology, and
^fRehabilitation Medicine,
^gInha Research Institute for Medical Sciences,
^hCenter for Advanced Medical Education by BK21 Project, Inha University College of Medicine, Incheon, Korea;
ⁱDepartment of Orthopedics, Molecular Science, and Technology, Ajou University Hospital, Suwon, Korea

Key Words. Human bone marrow cells • Granulocyte macrophage-colony stimulating factor • Spinal cord injury • Transplantation

Correspondence: Yoon Ha, M.D., Ph.D., Department of Neurosurgery, Inha University College of Medicine, 7-206, Sinheung-dong 3-ga, Jung-gu, Incheon 400-712, Korea. Telephone: +82-32-890-3449; Fax: +82-32-890-3099; e-mail: hayoon{at}inha.ac.kr

Received December 29, 2006; accepted for publication April 13, 2007.
First published online in STEM CELLS EXPRESS   April 26, 2007.



To assess the safety and therapeutic efficacy of autologous human bone marrow cell (BMC) transplantation and the administration of granulocyte macrophage-colony stimulating factor (GM-CSF), a phase I/II open-label and nonrandomized study was conducted on 35 complete spinal cord injury patients. The BMCs were transplanted by injection into the surrounding area of the spinal cord injury site within 14 injury days (n = 17), between 14 days and 8 weeks (n = 6), and at more than 8 weeks (n = 12) after injury. In the control group, all patients (n = 13) were treated only with conventional decompression and fusion surgery without BMC transplantation. The patients underwent preoperative and follow-up neurological assessment using the American Spinal Injury Association Impairment Scale (AIS), electrophysiological monitoring, and magnetic resonance imaging (MRI). The mean follow-up period was 10.4 months after injury. At 4 months, the MRI analysis showed the enlargement of spinal cords and the small enhancement of the cell implantation sites, which were not any adverse lesions such as malignant transformation, hemorrhage, new cysts, or infections. Furthermore, the BMC transplantation and GM-CSF administration were not associated with any serious adverse clinical events increasing morbidities. The AIS grade increased in 30.4% of the acute and subacute treated patients (AIS A to B or C), whereas no significant improvement was observed in the chronic treatment group. Increasing neuropathic pain during the treatment and tumor formation at the site of transplantation are still remaining to be investigated. Long-term and large scale multicenter clinical study is required to determine its precise therapeutic effect.

Disclosure of potential conflicts of interest is found at the end of this article.